病毒学报

参考文献

[1] de Martel C,Plummer M,Vignat J,Franceschi S.Worldwide burden of cancer attributable to HPV by site,country and HPV type[J]. Int J Cancer,2017,141(4):664-670.

[2] Bray F,Ferlay J,Soerjomataram I,Siegel R L,Torre L A, Jemal A. Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin,2018,68(6):394-424.

[3] HPV vaccine works against nine viral types[J]. Cancer Discov,2014 Jan;41):OF2.

[4] Li Z,Song S,He M,Wang D,Shi J,Liu X,Li Y,Chi X,Wei S,Yang Y,Wang Z,Li J,Qian H,Yu H,Zheng Q,Yan X,Zhao Q,Zhang J,Gu Y,Li S,Xia N. Rational design of a triple-type human papillomavirus vaccine by compromising viral-type specificity[J]. Nat Commun,2018,9(1):5360.

[5] de Villiers E M,Fauquet C,Broker T R,Bernard H U,zur Hausen H. Classification of papillomaviruses[J].Virology,2004,324(1):17-27.

[6] DiMaio D,Petti L M. The E5 proteins[J]. Virology,2013,445(1-2):99-114.

[7] Vande Pol S B,Klingelhutz A J. Papillomavirus E6oncoproteins[J]. Virology,2013,445(1-2):115-137.

[8] Roman A,Munger K. The papillomavirus E7 proteins[J]. Virology,2013,445(1-2):138-168.

[9] Cordeiro M N,De Lima R C P,Paolini F,Melo A,Campos A P F,Venuti A,De Freitas A C. Current research into novel therapeutic vaccines against cervical cancer[J]. Expert Rev Anticancer Ther,2018,18(4):365-376.

[10]Chabeda A,Yanez R J R,Lamprecht R,Meyers A E,Rybicki E P,Hitzeroth,II. Therapeutic vaccines for high-risk HPV-associated diseases[J]. Papillomavirus Res,2018,5:46-58.

[11]Lee S J,Yang A,Wu T C,Hung C F. Immunotherapy for human papillomavirus-associated disease and cervical cancer:review of clinical and translational research[J/OL]. J Gynecol Oncol,2016,27(5):e51.

[12]徐思慧.治疗性HPV DNA疫苗的研究进展[J].基础医学与临床，2015,35(3):421-424.

[13]Kim T J,Jin H T,Hur S Y,Yang H G,Seo Y B,Hong S R,Lee C W,Kim S,Woo J W,Park K S,Hwang Y Y,Park J,Lee I H,Lim K T,Lee K H,Jeong M S,Surh C D,Suh Y S,Park J S,Sung Y C.Clearance of persistent HPV infection and cervical lesion by therapeutic DNA vaccine in CIN3 patients[J]. Nat Commun,2014,5:5317.

[14]Bagarazzi M L,Yan J,Morrow M P,Shen X,Parker R L,Lee J C,Giffear M,Pankhong P,Khan A S,Broderick K E,Knott C,Lin F,Boyer J D,DraghiaAkli R,White C J,Kim J J,Weiner D B,Sardesai N Y. Immunotherapy against HPV16/18 generates potent TH1 and cytotoxic cellular immune responses[J]. Sci Transl Med,2012,4(155):155ra138.

[15]Trimble C L,Morrow M P,Kraynyak K A,Shen X,Dallas M,Yan J,Edwards L,Parker R L,Denny L,Giffear M,Brown A S,Marcozzi-Pierce K,Shah D,Slager A M,Sylvester A J,Khan A,Broderick K E,Juba R J,Herring T A,Boyer J,Lee J,Sardesai N Y,Weiner D B, Bagarazzi M L. Safety, efficacy, and immunogenicity of VGX-3100,a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18E6 and E7 proteins for cervical intraepithelial neoplasia2/3:a randomised,double-blind,placebo-controlled phase 2b trial[J]. The Lancet,2015,386(10008):2078-2088.

[16]Alvarez R D,Huh W K,Bae S,Lamb L S,Jr.,Conner M G,Boyer J,Wang C,Hung C F,Sauter E,Paradis M,Adams E A,Hester S,Jackson B E,Wu T C,Trimble C L. A pilot study of pNGVL4a-CRT/E7(detox)for the treatment of patients with HPV16+cervical intraepithelial neoplasia 2/3(CIN2/3)[J].Gynecol Oncol,2016,140(2):245-252.

[17]Granadillo M,Vallespi M G,Batte A,Mendoza O,Soria Y,Lugo V M,Torrens I. A novel fusion proteinbased vaccine comprising a cell penetrating and immunostimulatory peptide linked to human papillomavirus(HPV)type 16 E7 antigen generates potent immunologic and anti-tumor responses in mice[J]. Vaccine,2011,29(5):920-930.

[18]Coleman H N,Greenfield W W,Stratton S L,Vaughn R,Kieber A,Moerman-Herzog A M,Spencer H J,Hitt W C,Quick C M,Hutchins L F,Mackintosh S G,Edmondson R D,Erickson S W,Nakagawa M. Human papillomavirus type 16 viral load is decreased following a therapeutic vaccination[J]. Cancer Immunol Immunother,2016,65(5):563-573.

[19]Yang A,Farmer E,Wu T C,Hung C F. Perspectives for therapeutic HPV vaccine development[J]. J Biomed Sci,2016,23(1):75.

[20]Su J H,Wu A,Scotney E,Ma B,Monie A,Hung C F, Wu T C. Immunotherapy for cervical cancer:Research status and clinical potential[J]. BioDrugs,2010,24(2):109-129.

[21]K. Lin K D,Chien-Fu Hung,T-C Wu. Perspectives for Preventive and Therapeutic HPV Vaccines[J]. J.Formos.Med. Assoc,2010,109(1):4-24.

[22]Brun J L,Dalstein V,Leveque J,Mathevet P,Raulic P, Baldauf J J, Scholl S, Huynh B, Douvier S,Riethmuller D,Clavel C,Birembaut P,Calenda V,Baudin M,Bory J P. Regression of high-grade cervical intraepithelial neoplasia with TG4001 targeted immunotherapy[J/OL]. Am J Obstet Gynecol,2011,204(2):169. e1-8.

[23]Atherton M J,Stephenson K B,Nikota J K,Hu Q N,Nguyen A, Wan Y, Lichty B D. Preclinical development of peptide vaccination combined with oncolytic MG1-E6E7 for HPV-associated cancer[J].Vaccine,2018,36(16):2181-2192.

[24]Chen Z,Ozbun L,Chong N,Wallecha A,Berzofsky J A, Khleif S N. Episomal expression of truncated listeriolysin O in LmddA-LLO-E7 vaccine enhances antitumor efficacy by preferentially inducing expansions of CD4+FoxP3-and CD8+T cells[J]. Cancer Immunol Res,2014,2(9):911-922.

[25]Kawana K,Adachi K,Kojima S,Taguchi A,Tomio K,Yamashita A,Nishida H,Nagasaka K,Arimoto T,Yokoyama T,Wada-Hiraike O,Oda K,Sewaki T,Osuga Y,Fujii T. Oral vaccination against HPV E7 for treatment of cervical intraepithelial neoplasia grade 3(CIN3)elicits E7-specific mucosal immunity in the cervix of CIN3 patients[J]. Vaccine,2014,32(47):6233-6239.

[26]Santin A D, Bellone S, Palmieri M, Zanolini A,Ravaggi A, Siegel E R, Roman J J, Pecorelli S,Cannon M J. Human papillomavirus type 16 and 18 E7-pulsed dendritic cell vaccination of stage IB or IIA cervical cancer patients:a phase I escalating-dose trial[J]. J Virol,2008,82(4):1968-1979.

[27]Santin A D, Bellone S, Palmieri M, Ravaggi A,Romani C,Tassi R,Roman J J,Burnett A,Pecorelli S,Cannon M J. HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities[J].Gynecol Oncol,2006,100(3):469-478.

[28]Diniz M O,Ferreira L C. Enhanced anti-tumor effect of a gene gun-delivered DNA vaccine encoding the human papillomavirus type 16 oncoproteins genetically fused to the herpes simplex virus glycoprotein D[J]. Braz J Med Biol Res,2011,44(5):421-427.

[29]Yang B,Yang A,Peng S,Pang X,Roden R B,Wu T C,Hung C F. Co-administration with DNA encoding papillomavirus capsid proteins enhances the antitumor effects generated by therapeutic HPV DNA vaccination[J]. Cell Biosci,2015,5:35.

[30]Van Damme P,Bouillette-Marussig M,Hens A,De Coster I,Depuydt C,Goubier A,Van Tendeloo V,Cools N,Goossens H,Hercend T,Timmerman B,Bissery M C. GTL001, A therapeutic vaccine for women infected with human papillomavirus 16 or 18 and normal cervical cytology:Results of a phase I clinical trial[J]. Clin Cancer Res,2016,22(13):3238-3248.

[31]Wick D A,Martin S D,Nelson B H,Webb J R.Profound CD8+T cell immunity elicited by sequential daily immunization with exogenous antigen plus the TLR3 agonist poly(I:C)[J]. Vaccine,2011,29(5):984-993.

[32]Monroy-Garcia A,Gomez-Lim M A,Weiss-Steider B,Hernandez-Montes J,Huerta-Yepez S,Rangel-Santiago J F, Santiago-Osorio E, Mora Garcia Mde L.Immunization with an HPV-16 L1-based chimeric viruslike particle containing HPV-16 E6 and E7 epitopes elicits long-lasting prophylactic and therapeutic efficacy in an HPV-16 tumor mice model[J]. Arch Virol,2014,159(2):291-305.

[33]Massarelli E, William W, Johnson F, Kies M,Ferrarotto R,Guo M,Feng L,Lee J J,Tran H,Kim Y U,Haymaker C,Bernatchez C,Curran M,Zecchini Barrese T, Rodriguez Canales J, Wistuba I, Li L,Wang J,van der Burg S H,Melief C J,Glisson B.Combining immune checkpoint blockade and tumorspecific vaccine for patients with incurable human papillomavirus 16-related cancer:A phase 2 clinical trial[J]. JAMA Oncol,2019,5(1):67-73.

[34]Kim D,Hung C F,Wu T C,Park Y M. DNA vaccine with alpha-galactosylceramide at prime phase enhances anti-tumor immunity after boosting with antigenexpressing dendritic cells[J]. Vaccine,2010,28(45):7297-7305.

[35]Ott P A,Hu Z,Keskin D B,Shukla S A,Sun J,Bozym D J,Zhang W,Luoma A,Giobbie-Hurder A,Peter L,Chen C,Olive O,Carter T A,Li S,Lieb D J,Eisenhaure T,Gjini E,Stevens J,Lane W J,Javeri I,Nellaiappan K,Salazar A M,Daley H,Seaman M,Buchbinder E I,Yoon C H,Harden M,Lennon N,Gabriel S,Rodig S J,Barouch D H,Aster J C,Getz G,Wucherpfennig K,Neuberg D,Ritz J,Lander E S,Fritsch E F,Hacohen N,Wu C J. An immunogenic personal neoantigen vaccine for patients with melanoma[J]. Nature,2017,547(7662):217-221.

[36]Sahin U,Derhovanessian E,Miller M,Kloke B P,Simon P, Lower M, Bukur V, Tadmor A D,Luxemburger U,Schrors B,Omokoko T,Vormehr M,Albrecht C,Paruzynski A,Kuhn A N,Buck J,Heesch S,Schreeb K H,Muller F,Ortseifer I,Vogler I, Godehardt E, Attig S, Rae R, Breitkreuz A,Tolliver C,Suchan M,Martic G,Hohberger A,Sorn P,Diekmann J,Ciesla J,Waksmann O,Bruck A K,Witt M, Zillgen M, Rothermel A, Kasemann B,Langer D,Bolte S,Diken M,Kreiter S,Nemecek R,Gebhardt C,Grabbe S,Holler C,Utikal J,Huber C,Loquai C, Tureci O. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer[J]. Nature,2017,547(7662):222-226.